Adtran expands ALM with deep PON assurance for FTTX network monitoring
12.7.2023 15:00:00 EEST | Business Wire | Press release
Adtran today announced the extension of its ALM infrastructure assurance solution, enabling simple and cost-efficient fiber monitoring of passive optical networks (PON). Already widely deployed in other types of network architecture, the technology now provides deep PON assurance, enabling communication service providers (CSPs) to monitor their entire PON infrastructure for any faults or degradation. Until today, assuring PON networks was challenging and expensive. Now there’s a simple and cost-efficient way to leverage real-time insight so that maintenance teams can quickly locate and resolve issues before they affect customers. PON networks are critical for the delivery of high-speed connectivity to millions of homes and businesses. The ability to comprehensively monitor this essential part of the network will deliver major benefits in terms of performance, reliability and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230712070000/en/
Adtran’s ALM deep PON assurance technology is a unique solution that will provide CSPs with granular insight into their PON networks. (Photo: Business Wire)
“The evolution of our ALM device to include deep PON assurance marks a major milestone for the industry and for our company. It’s the first time since the merger of Adtran and ADVA that our combined technology teams have released a solution that shows the close synergies between the organizations,” said Christoph Glingener, CTO of Adtran. “We are major players in both the PON and fiber assurance spaces with rapidly growing market shares. By utilizing our expertise in these areas, we’ve developed a unique solution that could have an enormous impact on CSPs’ opex costs. For the first time, they will be able to both monitor and manage their PON networks in one pane of glass. This will provide CSPs with more insight and granular control than ever before. And because our deep PON assurance technology works through splitters, we’re able to keep capex costs low.”
Adtran’s ALM technology for in-service fiber monitoring is available immediately and can be easily integrated into existing fiber-to-the-home, fiber-to-the-business or any other FTTX network. The non-intrusive, service-agnostic deep PON assurance solution eliminates the need for demarcation reflectors in the field, ensuring compatibility with any existing PON network while reducing operational complexity. Offering valuable insights into passive network quality, it acts like a radar to pinpoint the location of issues. Featuring fanless operation and low-power consumption, the ultra-compact ALM enhances operational efficiency and sustainability. CSPs can quickly check the status of their PON network through Adtran’s web-based GUI, Ensemble Controller network management platform or a dedicated mobile application for on-the-go access.
“Our ALM assurance platform is already recognized as the gold standard for fiber monitoring in optical networks. With our deep PON assurance innovation, we’re extending its benefits to many more customers, enabling FTTX network operators to dramatically shorten repair cycles and avoid unnecessary truck rolls. This breakthrough technology will transform how CSPs manage their PON infrastructure, enabling them to provide a better customer experience while reducing costs and improving sustainability,” commented Sander Jansen, GM of Infrastructure Monitoring at Adtran. “We’re excited to help our customers unlock the full potential of their PON networks and provide them with the real-time insights they need to optimize performance and reduce their carbon footprint.”
Further information on Adtran’s ALM deep PON assurance technology is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712070000/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
